Filtered By:
Source: Thrombosis and Haemostasis

This page shows you your search results in order of date. This is page number 17.

Order by Relevance | Date

Total 528 results found since Jan 2013.

Atrial fibrillation in patients with embolic stroke of undetermined source during 3 years of prolonged monitoring with an implantable loop recorder.
CONCLUSIONS: In ESUS patients, early implantation of an ILR with cardiac monitoring and remote transmission over a 3-year period detects AF in 41.4 % and results in oral anticoagulation in 82% of these patients. PMID: 33401327 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - January 5, 2021 Category: Hematology Authors: Kitsiou A, Rogalewski A, Kalyani M, Deelawar S, Tribunyan S, Greeve I, Minnerup J, Israel C, Schäbitz W Tags: Thromb Haemost Source Type: research

High Thrombin Generation after Acute Ischemic Stroke or Transient Ischemic Attack Is Associated with a Reduced Risk of Recurrence: An Observational Cohort Study.
Abstract Thrombin is increasingly recognized to be of importance for cardiovascular disease. The aim of this study was to investigate the prognostic value of thrombin generation variables in a cohort of patients with acute ischemic stroke (AIS) or transient ischemic attack (TIA). Thrombin generation potential measured by calibrated automated thrombogram (CAT) and prothrombin fragment F1 + 2 was determined in the acute and convalescent phases for a cohort of 190 patients with AIS/TIA. Microvesicle (MV)-induced thrombin generation potential was determined for a subset of patients using modified CAT. Primary outc...
Source: Thrombosis and Haemostasis - December 12, 2020 Category: Hematology Authors: Lundström A, Änggårdh-Rooth E, Mobarrez F, Thålin C, Gigante B, Laska AC, Wallén H Tags: Thromb Haemost Source Type: research

Age-dependent anticoagulant therapy for atrial fibrillation patients with intermediate risk of ischemic stroke: A nationwide population-based study.
CONCLUSIONS: Age is an important determinant of ischemic stroke and composite outcome in intermediate-risk AF patients. The benefit of OAC therapy for these AF patients appears to have an age threshold (age ≥ 55 years). PMID: 33307565 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - December 11, 2020 Category: Hematology Authors: Choi SY, Kim MHH, Lee KM, Cho YR, Park JS, Yun SC, Lip GY Tags: Thromb Haemost Source Type: research

Embolic stroke of undetermined source: The need for an integrated and holistic approach to care.
Abstract No Abstract. PMID: 33307563 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - December 11, 2020 Category: Hematology Authors: Guo Y, Zhang J, Lip GY Tags: Thromb Haemost Source Type: research

Stroke and Thromboembolism in Warfarin-Treated Patients with Atrial Fibrillation: Comparing the CHA2DS2-VASc and GARFIELD-AF Risk Scores.
CONCLUSIONS: In a warfarin-treated trial cohort of AF patients, both CHA2DS2-VASc and GARFIELD-AF Stroke scores were associated with adjudicated TE events, with modest predictive capacity. Simpler CHA2DS2-VASc score improved discriminatory capacity compared to more complex GARFIELD-AF score, demonstrating improved clinical usefulness and net clinical benefit. PMID: 33296920 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - December 9, 2020 Category: Hematology Authors: Proietti M, Rivera-Caravaca JM, Esteve-Pastor MA, Marín F, Lip GY Tags: Thromb Haemost Source Type: research

Reactome pathway analysis of venous thromboembolism, peripheral artery disease, stroke, and coronary artery.
Abstract No abstract. PMID: 33212516 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - November 19, 2020 Category: Hematology Authors: Zöller BA, Svensson P, Huang W, Ji J Tags: Thromb Haemost Source Type: research

Hyperglycemia exacerbates ischemic stroke outcome independent of platelet glucose uptake.
CONCLUSION: Hyperglycemia aggravates ischemic stroke outcome independent of platelet glucose uptake. Furthermore, we demonstrated that hyperglycemia primes procoagulant platelet formation. This underlines the therapeutic potential for strategies targeting procoagulant platelet formation for the treatment of acute ischemic stroke. PMID: 33118271 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - October 28, 2020 Category: Hematology Authors: Denorme F, Portier I, Kosaka Y, Campbell RA Tags: J Thromb Haemost Source Type: research

Long-Term Treatment with Apixaban in Patients with Atrial Fibrillation: Outcomes during the Open-Label Extension following AVERROES.
CONCLUSION:  During the open-label extension, annual rates of stroke or systemic embolism, hemorrhagic stroke, and major bleeding remained as low as those observed during apixaban treatment in AVERROES. These data support the long-term efficacy and safety of apixaban in patients with atrial fibrillation. PMID: 33011964 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - October 3, 2020 Category: Hematology Authors: Benz AP, Eikelboom JW, Yusuf S, Hohnloser SH, Kahl A, Beresh H, Balasubramanian K, Healey JS, Connolly SJ Tags: Thromb Haemost Source Type: research

Interactive Effects of a Combination of the HDAC3 and HDAC9 Genes with Diabetes Mellitus on the Risk of Ischemic Stroke.
CONCLUSION:  Our results suggested that the combination of the HDAC3 and HDAC9 genes with a history of diabetes mellitus could exacerbate the deterioration of atherosclerosis, thereby increasing the risk of IS. Further studies are warranted to explore our results in other populations. PMID: 32961570 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - September 21, 2020 Category: Hematology Authors: Chiou HY, Bai CH, Lien LM, Hu CJ, Jeng JS, Tang SC, Lin HJ, Hsieh YC Tags: Thromb Haemost Source Type: research

Coagulation factor XII, XI, and VIII activity levels and secondary events after first ischemic stroke.
CONCLUSIONS: In our study of mild to moderate ischemic stroke patients, high activity levels of FXI and FVIII but not FXII were associated with worse vascular outcomes in the three-year period after first ischemic stroke. PMID: 32935900 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - September 15, 2020 Category: Hematology Authors: Rohmann JL, Huo S, Sperber PS, Piper SK, Rosendaal FR, Heuschmann PU, Endres M, Liman TG, Siegerink B Tags: J Thromb Haemost Source Type: research

von Willebrand Factor Antigen, von Willebrand Factor Propeptide, and ADAMTS13 in Carotid Stenosis and Their Relationship with Cerebral Microemboli.
DISCUSSION:  VWF:Ag expression, a marker of endothelial ± platelet activation, is enhanced in recently symptomatic versus asymptomatic carotid stenosis patients, including in MES-ve patients, and decreases with ADAMTS13 activity over time following atherosclerotic TIA/ischemic stroke. PMID: 32932544 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - September 14, 2020 Category: Hematology Authors: Murphy SJX, Lim ST, Hickey F, Kinsella JA, Smith DR, Tierney S, Egan B, Feeley TM, Murphy SM, Collins DR, Coughlan T, O'Neill D, Harbison JA, Madhavan P, O'Neill SM, Colgan MP, O'Donnell JS, O'Sullivan JM, Hamilton G, McCabe DJH Tags: Thromb Haemost Source Type: research

Antithrombin p.Thr147Ala: The First Founder Mutation in People of African Origin Responsible for Inherited Antithrombin Deficiency.
CONCLUSION:  Antithrombin p.Thr147Ala, responsible for antithrombin type II heparin binding site deficiency, is the first founder mutation reported in people of African ancestry. This study further emphasizes the limitations of commercial methods to diagnose this specific subtype. PMID: 32920809 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - September 12, 2020 Category: Hematology Authors: Orlando C, de la Morena-Barrio B, Pareyn I, Vanhoorelbeke K, Martínez-Martínez I, Vicente V, Corral J, Jochmans K, de la Morena-Barrio ME Tags: Thromb Haemost Source Type: research

Edoxaban versus Warfarin in Patients with Atrial Fibrillation at the Extremes of Body Weight: An Analysis from the ENGAGE AF-TIMI 48 Trial.
CONCLUSION:  Patients with LBW in ENGAGE AF-TIMI 48 had in general a more fragile clinical status and poorer international normalized ratio control. The pharmacokinetic/pharmacodynamic profile of edoxaban was consistent across extremes of BW, resulting in similar efficacy compared with warfarin, while major or clinically relevant non-MB and net outcomes were most favorable with edoxaban as compared to warfarin in LBW patients. PMID: 32920808 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - September 12, 2020 Category: Hematology Authors: Boriani G, Ruff CT, Kuder JF, Shi M, Lanz HJ, Antman EM, Braunwald E, Giugliano RP Tags: Thromb Haemost Source Type: research

Impact of different anticoagulation management strategies on outcomes in atrial fibrillation: Dutch and Belgian results from the GARFIELD-AF registry.
CONCLUSIONS: In GARFIELD-AF, despite similar characteristics, patients on anticoagulants were treated differently in NL and BE. Although the rate of major bleeding was 33% higher in NL, variations in bleeding, mortality and TE rates were not statistically significant. PMID: 32886853 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - September 3, 2020 Category: Hematology Authors: Seelig J, Hemels MEW, Xhaët O, Bongaerts MCM, de Wolf A, Groenemeijer BE, Heyse A, Hoogslag P, Voet J, Herrman JR, Vervoort G, Hermans W, Wollaert B, Boersma LVA, Hermans K, Lucassen A, Verstraete S, Adriaansen HJ, Mairesse GH, Terpstra WF, Faes D, Piete Tags: J Thromb Haemost Source Type: research

Atrial Cardiopathy and Likely Pathogenic Patent Foramen Ovale in Embolic Stroke of Undetermined Source.
CONCLUSION:  The presence of atrial cardiopathy is inversely related to the presence of likely pathogenic PFO in patients with ESUS. PMID: 32877955 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - September 1, 2020 Category: Hematology Authors: Leventis IA, Sagris D, Strambo D, Perlepe K, Sirimarco G, Nannoni S, Korompoki E, Manios E, Makaritsis K, Vemmos K, Michel P, Ntaios G Tags: Thromb Haemost Source Type: research